PHASE II CLINICAL TRIAL IN PATIENTS WITH PARKINSON’S DISEASE

In the perspective of developing a new therapeutic approach, B&A Therapeutics has applied for an international patent for the use of a diuretic, Bumetanidev a blocker of the chloride ions importer NKCC1, in the treatment of Parkinson’s disease. The use of bumetanide as a treatment comes from our basic research work. The dysfunctions of interneurons of the striatum that use GABA (gamma-aminobutyric acid) alone or together with acetylcholine as a neurotransmitter, are abolished by bumétanide administered in vivo in the adult mouse model of Parkinson disease before in vitro experiments (Lozovaya et al, 2018).

Following the encouraging results obtained during a pilot study conducted in 4 patients with Parkinson’s disease (Damier et al, 2016), B&A Therapeutics set up a phase II clinical trial in several French expert centers to demonstrate the efficacy of the molecule in the treatment of Parkinson Disease.

CLINICAL RESEARCH

Damier P, Hammond C, Ben-Ari Y.

Bumetanide to Treat Parkinson Disease : A Report of 4 Cases.

Clin Neuropharmacol. 2016 Jan-Feb;39(1):57-9.

Read article

Plus d'informations